CD19 and hematologic disorder: CAR-NK cells targeting several different antigens, including CD138, SLAMF7, CD19, CD20, CD33 and CD123, using both primary NK cells and NK cell lines, are currently being investigated in pre-clinical studies of both solid and hematological malignancies (96, 97).